UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

Cancer discovery, 2022-05, Vol.12 (5), p.1233-1247

2022

Volltextzugriff (PDF)

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

Communications biology, 2020-12, Vol.3 (1), p.776-776, Article 776

2020

Volltextzugriff (PDF)

CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma

Cancer research (Chicago, Ill.), 2022-03, Vol.82 (6), p.1110-1127

2022

Volltextzugriff (PDF)

Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling

Disease models & mechanisms, 2022-01, Vol.15 (1)

2022

Volltextzugriff (PDF)

RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation

Disease models & mechanisms, 2021-02, Vol.14 (2)

2021

Volltextzugriff (PDF)

Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR -Mutated Lung Cancer

JCO precision oncology, 2019 (3), p.1-8

2019

Volltextzugriff (PDF)

First person – Roger Smith and Igor Odintsov

Disease models & mechanisms, 2022-01, Vol.15 (1)

2022

Volltextzugriff (PDF)

Vepafestinib: a RET-selective inhibitor with enhanced CNS penetrance targets therapy-resistant mutants

Nature cancer, 2023-09, Vol.4 (9), p.1220-1221

2023

Volltextzugriff (PDF)

Prognostic and predictive biomarkers in non-small cell lung carcinoma

Pathology, 2024-03, Vol.56 (2), p.192-204

2024

Volltextzugriff (PDF)

Abstract 935: Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.935-935

2021

Volltextzugriff (PDF)

Abstract P201: Zenocutuzumab is an effective HER2/HER3 Biclonics® antibody in cancers with NRG1 fusions

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P201-P201

2021

Volltextzugriff (PDF)

A visual-language foundation model for computational pathology

Nature medicine, 2024-03, Vol.30 (3), p.863-874

2024

Volltextzugriff (PDF)

Pulmonary Vasoconstriction and Vascular Remodeling Play Role in Reactive Pulmonary Hypertension in Rats

The FASEB journal, 2018-04, Vol.32 (S1), p.lb316-lb316

2018

Volltextzugriff (PDF)

Integrating Molecular Sequencing Into the Pathological Diagnosis of Clinically Suspected Non–Small Cell Lung Carcinomas

Modern pathology, 2023-05, Vol.36 (5), p.100126-100126, Article 100126

2023

Volltextzugriff (PDF)

A blast from the past: ROS1 on the brain

Oncotarget, 2019-03, Vol.10 (18), p.1664-1666

2019

Volltextzugriff (PDF)

Myxoid Inflammatory Myofibroblastic Sarcoma: Clinicopathologic Analysis of 25 Cases of a Distinctive Sarcoma With Deceptively Bland Morphology and Aggressive Clinical Behavior

The American journal of surgical pathology, 2024-08, Vol.48 (8), p.1005-1016

2024

Volltextzugriff (PDF)

The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions

Clinical cancer research, 2021-06, Vol.27 (11), p.3154-3166

2021

Volltextzugriff (PDF)

Infantile Sinonasal Myxoma Is Clinically and Genetically Distinct From Other Myxomas of the Craniofacial Bones and From Desmoid Fibromatosis

The American journal of surgical pathology, 2023-11, Vol.47 (11), p.1301-1315

2023

Volltextzugriff (PDF)

HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies

Journal of thoracic oncology, 2024-01, Vol.19 (1), p.106-118

2024

Volltextzugriff (PDF)

Landscape of targetable alterations discovered by next generation sequencing demonstrates the role a community hospital can play in precision-guided oncology: Experience from Lenox Hill Hospital

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e19279-e19279

2020

Volltextzugriff (PDF)

Abstract 1111: MYC promotes tyrosine kinase inhibitor resistance in ROS1 fusion positive lung cancers

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1111-1111

2021

Volltextzugriff (PDF)

HER2 antibody-drug conjugates are active against desmoplastic small round cell tumor

Clinical cancer research, 2024-08

2024

Volltextzugriff (PDF)

MODL-01. TRACTABLE PATIENT-DERIVED MODELS FOR PRECLINICAL THERAPEUTIC STUDIES OF CNS METASTASES

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (Supplement_7), p.vii290-vii291

2022

Volltextzugriff (PDF)

Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor

Clinical cancer research, 2021-02, Vol.27 (4), p.1184-1194

2021

Volltextzugriff (PDF)

Comparison of TAS0953/HM06 and selpercatinib in RET fusion-driven preclinical disease models of intracranial metastases

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.2024-2024

2022

Volltextzugriff (PDF)

1 – 25 von 84

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(65)

Publikationsform

Sprache

Englisch
(83)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(34)
Life Sciences & Biomedicine
(24)
Humans
(15)
Oncology
(14)
Lung Neoplasms - Genetics
(8)
Pathology
(8)
Technology
(7)
Carcinoma, Non-Small-Cell Lung - Genetics
(6)
Mutation
(6)
Cell Biology
(5)
Lung Neoplasms - Drug Therapy
(5)
Patients
(5)
Animals
(4)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(4)
Cell Line, Tumor
(4)
Computer Science
(4)
Computer Science, Theory & Methods
(4)
Female
(4)
Gene Expression
(4)
Kinases
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma

Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling

RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation

Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR -Mutated Lung Cancer

First person – Roger Smith and Igor Odintsov

Vepafestinib: a RET-selective inhibitor with enhanced CNS penetrance targets therapy-resistant mutants

Prognostic and predictive biomarkers in non-small cell lung carcinoma

Abstract 935: Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions

Abstract P201: Zenocutuzumab is an effective HER2/HER3 Biclonics® antibody in cancers with NRG1 fusions

A visual-language foundation model for computational pathology

Pulmonary Vasoconstriction and Vascular Remodeling Play Role in Reactive Pulmonary Hypertension in Rats

Integrating Molecular Sequencing Into the Pathological Diagnosis of Clinically Suspected Non–Small Cell Lung Carcinomas

A blast from the past: ROS1 on the brain

Myxoid Inflammatory Myofibroblastic Sarcoma: Clinicopathologic Analysis of 25 Cases of a Distinctive Sarcoma With Deceptively Bland Morphology and Aggressive Clinical Behavior

The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions

Infantile Sinonasal Myxoma Is Clinically and Genetically Distinct From Other Myxomas of the Craniofacial Bones and From Desmoid Fibromatosis

HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies

Landscape of targetable alterations discovered by next generation sequencing demonstrates the role a community hospital can play in precision-guided oncology: Experience from Lenox Hill Hospital

Abstract 1111: MYC promotes tyrosine kinase inhibitor resistance in ROS1 fusion positive lung cancers

HER2 antibody-drug conjugates are active against desmoplastic small round cell tumor

MODL-01. TRACTABLE PATIENT-DERIVED MODELS FOR PRECLINICAL THERAPEUTIC STUDIES OF CNS METASTASES

Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor

Comparison of TAS0953/HM06 and selpercatinib in RET fusion-driven preclinical disease models of intracranial metastases

Suchergebnisse filtern